|1.||Persson, Bo-Eric: 14 articles (06/2015 - 10/2008)|
|2.||Klotz, Laurence: 8 articles (11/2015 - 12/2008)|
|3.||Boccon-Gibod, Laurent: 8 articles (10/2014 - 12/2008)|
|4.||Crawford, E David: 6 articles (12/2014 - 06/2009)|
|5.||Olesen, Tine Kold: 6 articles (07/2012 - 11/2008)|
|6.||Jensen, Jens-Kristian: 6 articles (09/2011 - 10/2008)|
|7.||Miller, Kurt: 5 articles (06/2015 - 05/2010)|
|8.||Tombal, Bertrand: 5 articles (12/2014 - 10/2008)|
|9.||van der Meulen, Egbert: 4 articles (01/2013 - 06/2011)|
|10.||Tomillero, A: 4 articles (09/2010 - 06/2008)|
|1.||Prostatic Neoplasms (Prostate Cancer)
04/01/2013 - "Degarelix provides a cost-effective treatment for ADT among patients with locally advanced prostate cancer."
12/01/2009 - "Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer."
01/01/2014 - "We performed a systematic review and meta-analysis to assess the efficacy and tolerability of degarelix for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer (PCa). "
07/01/2012 - "[The efficacy of degarelix on LUTS (Lower urinary tract symptoms) relief in patients with prostate cancer]."
03/01/2015 - "Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study."
|2.||Cardiovascular Diseases (Cardiovascular Disease)
11/01/2011 - "First time cardiovascular disease events were reported in 92 men in the year before study entry and in 168 after degarelix treatment. "
11/01/2011 - "Degarelix dose and schedule were not independently associated with cardiovascular disease events. "
11/01/2011 - "In contrast, event rates appeared higher after degarelix treatment in men with cardiovascular disease at baseline (5.3 to 10.5 events per 100 person-years, p = 0.0013). "
11/01/2011 - "Event rates were similar before and after degarelix treatment in the total population (5.5 vs 6.1/100 person-years, p = 0.45) and in men without cardiovascular disease (5.6 vs 4.3/100 person-years, p = 0.11). "
11/01/2011 - "In men with prostate cancer observed rates of cardiovascular disease events were similar before and after degarelix treatment. "
03/01/2007 - "In both studies, degarelix demonstrated a sustained inhibition of tumor growth at least comparable with surgical castration. "
01/01/2014 - "In addition to GnRH agonists and antagonists (i.e., degarelix), cytotoxic GnRH-based bioconjugates, delivering chemotherapeutic drugs to cancer cells expressing the GnRH-R, were developed and reported to exert antitumor effects on CRPC cells; some of them (i.e., AN-152) have already entered clinical trials. "
06/01/2010 - "The more rapid fall in testosterone obtained with degarelix, without an initial surge, did not translate into lower mortality (there were only 2 cancer deaths) or fewer adverse effects during the first month of treatment. "
08/01/2001 - "Tumor growth inhibition induced by anti-hormone therapy was linked to the hormone deprivation degree, more important and more stable with FE 200486 than with D-Trp(6)-luteinizing-hormone releasing hormone. "
03/01/2007 - "We report in this study that degarelix produces a fast and sustained suppression of the pituitary gonadal axis in rats and a similar inhibition of tumor growth compared with surgical castration in the Dunning R-3327H rat carcinoma model. "
02/01/2013 - "Degarelix is generally well tolerated, with no reports of systemic allergic reactions in any clinical studies. "
01/01/2013 - "Degarelix is usually well tolerated, with limited toxicity and no evidence of systemic allergic reactions in clinical studies. "
07/01/2012 - "Other than minor injection-site reactions, degarelix is generally well tolerated, without systemic allergic reactions and with most adverse events consistent with androgen suppression or the underlying condition. "
01/01/2009 - "Degarelix was well tolerated, with uneventful toxicology and no evidence of systemic allergic reactions. "
06/01/2011 - "Degarelix is one of a newer generation of antagonists which, in a comprehensive and ongoing clinical development programme, has been shown to provide rapid, profound and sustained testosterone suppression without the systemic allergic reactions associated with earlier antagonists. "
01/01/2009 - "Adverse effects of degarelix in clinical trials were mild and relatively uncommon and included flushing reactions, injection-site pain, weight gain, and increases in serum transaminase levels. "
06/01/2010 - "Reactions at the injection site (pain, erythema) were far more frequent with degarelix than with leuprorelin, affecting respectively about 40% and fewer than 1% of patients. "
09/01/2012 - "The results of the clinical trials (36 months) demonstrate that degarelix, compared to high-dose leuprorelin (7.5 mg), suppresses levels of testosterone and PSA (Prostate-Specific Antigen) more rapidly and reduces levels of FSH and musculoskeletal events associated with treatment (pain, muscle weakness, spasms, oedema/joint stiffness, arthralgia, osteoporosis and osteopoenia) to a greater extent. "
|1.||Gonadotropin-Releasing Hormone (GnRH)
|7.||Prostate-Specific Antigen (Semenogelase)
|8.||LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)
|10.||ruberythric acid (AlP)